Biodistribution and Metabolism Studies of Lipid Nanoparticle- Formulated Internally [3H]-Labeled siRNA in Mices

Drug Metabolism and Disposition

Volumn 42, Issue 3, 2014, Pages 431-440

  Christensen, Jesper ^a   Litherland, Karine ^a   Faller, Thomas ^a   Van De Kerkhof, Esther ^a   Natt, Francois ^a   Hunziker, Jürg ^a   Boos, Julien ^a   Beuvink, Iwan ^a   Bowman, Keith ^b   Baryza, Jeremy ^b   Beverly, Mike ^b   Vargeese, Chandra ^b   Heudi, Olivier ^a   Stoeckli, Markus ^a   Krauser, Joel ^a   Swart, Piet ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; AUTORADIOGRAPHY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; DRUG STABILITY; INJECTIONS, INTRAVENOUS; LIPIDS; MALE; MICE; MICE, INBRED STRAINS; NANOPARTICLES; RNA, SMALL INTERFERING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TISSUE DISTRIBUTION; TRITIUM; WHOLE-BODY COUNTING;

EID: 84893869383     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.055434     Document Type: Article

References (26)

1. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, and Davis ME (2007) Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 104:15549-15554.
2. Behlke MA (2008) Chemical modification of siRNAs for in vivo use. Oligonucleotides 18: 305-319.
3. Boos JA, Kirk DW, Piccolotto ML, Zuercher W, Gfeller S, Neuner P, Dattler A, Wishart WL, Von Arx F, and Beverly M, et al. (2013) Whole-body scanning PCR; a highly sensitive method to study the biodistribution of mRNAs, noncoding RNAs and therapeutic oligonucleotides. Nucleic Acids Res 41:e145.
4. Burnett JC, Rossi JJ, and Tiemann K (2011) Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 6:1130-1146.
5. Christensen J, Litherland K, Faller T, van de Kerkhof E, Natt F, Hunziker J, Krauser J, and Swart P (2013) Metabolism studies of unformulated internally [3H]-labeled short interfering RNAs in mice. Drug Metab Dispos 41:1211-1219.
6. Christensen J, Natt F, Hunziker J, Krauser J, and Swart P (2012) Tritium labeling of full-length small interfering RNAs. J Labelled Comp Radiopharm 55:189-196.
7. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
8. de Wolf HK, Snel CJ, Verbaan FJ, Schiffelers RM, Hennink WE, and Storm G (2007) Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration. Int J Pharm 331:167-175.
9. Gao S, Dagnaes-Hansen F, Nielsen EJB, Wengel J, Besenbacher F, Howard KA, and Kjems J (2009) The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther 17:1225-1233.
10. Hatanaka K, Asai T, Koide H, Kenjo E, Tsuzuku T, Harada N, Tsukada H, and Oku N (2010) Development of double-stranded siRNA labeling method using positron emitter and its in vivo trafficking analyzed by positron emission tomography. Bioconjug Chem 21:756-763.
11. Huang L, Sullenger B, and Juliano R (2010) The role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides. J Drug Target 18:567-574.
12. Juliano R, Bauman J, Kang H, and Ming X (2009) Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm 6:686-695.
13. Kawakami S and Hashida M (2007) Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab Pharmacokinet 22:142-151.
14. Malek A, Merkel O, Fink L, Czubayko F, Kissel T, and Aigner A (2009) In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol Appl Pharmacol 236:97-108.
15. Merkel OM, Librizzi D, Pfestroff A, Schurrat T, Béhé M, and Kissel T (2009a) In vivo SPECT and real-time gamma camera imaging of biodistribution and pharmacokinetics of siRNA delivery using an optimized radiolabeling and purification procedure. Bioconjug Chem 20:174-182.
16. Merkel OM, Librizzi D, Pfestroff A, Schurrat T, Buyens K, Sanders NN, De Smedt SC, Béhé M, and Kissel T (2009b) Stability of siRNA polyplexes from poly(ethylenimine) and poly (ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging. J Control Release 138:148-159.
17. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, and Jadhav V, et al. (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23:1002-1007.
18. Mudd SR, Trubetskoy VS, Blokhin AV, Weichert JP, and Wolff JA (2010) Hybrid PET/CT for noninvasive pharmacokinetic evaluation of dynamic PolyConjugates, a synthetic siRNA delivery system. Bioconjug Chem 21:1183-1189.
19. Rettig GR and Behlke MA (2012) Progress toward in vivo use of siRNAs-II. Mol Ther 20: 483-512.
20. Richmond CR, Langham WH, and Trujillo TT (1962) Comparative metabolism of tritiated water by mammals. J Cell Comp Physiol 59:45-53.
21. Semple SC, Akinc A, Chen JX, Sandhu AP, Mui BL, Cho CK, Sah DWY, Stebbing D, Crosley EJ, and Yaworski E, et al. (2010) Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28:172-176.
22. Sonoke S, Ueda T, Fujiwara K, Sato Y, Takagaki K, Hirabayashi K, Ohgi T, and Yano J (2008) Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Cancer Res 68:8843-8851.
23. Van de Water FM, Boerman OC, Wouterse AC, Peters JGP, Russel FGM, and Masereeuw R (2006) Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 34:1393-1397.
24. Wang Y, Li ZG, Han Y, Liang LH, and Ji AM (2010b) Nanoparticle-based delivery system for application of siRNA in vivo. Curr Drug Metab 11:182-196.
25. Wang J, Lu Z, Wientjes MG, and Au JL (2010a) Delivery of siRNA therapeutics: barriers and carriers. AAPS J 12:492-503.
26. Wei J, Jones J, Kang J, Card A, Krimm M, Hancock P, Pei Y, Ason B, Payson E, and Dubinina N, et al. (2011) RNA-induced silencing complex-bound small interfering RNA is a determinant of RNA interference-mediated gene silencing in mice. Mol Pharmacol 79:953-963.